Background Individuals living in endemic areas acquire immunity to malaria following
repeated parasite exposure. We sought to assess the controlled human malaria infection …

The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the current
leading blood-stage malaria vaccine candidate. PfRH5 functions as part of the pentameric …

T-follicular helper (Tfh) cells are key drivers of antibodies that protect from malaria. However,
little is known regarding the host and parasite factors that influence Tfh and functional …

Introduction Malaria represents a public health challenge in tropical and subtropical regions,
and currently deployed control strategies are likely insufficient to drive elimination of malaria …

Highlights•Treatment failure with traditional drugs implores exploration of novel
strategies.•Host-directed therapy has been successful to treat infectious …

Background: There are no licensed vaccines against Plasmodium vivax, the most common
cause of malaria outside of Africa. Methods: We conducted two Phase I/IIa clinical trials to …

Highlights•Vaccine development during the COVID-19 pandemic lacked thorough insight of
CoPs.•CoPs must go beyond simple quantitative antibody blocking.•Interplay between …

Malaria, caused by infection with Plasmodium parasites, drives multiple regulatory
responses across the immune landscape. These regulatory responses help to protect …

Plasmodium falciparum cysteine-rich protective antigen (CyRPA) is a conserved component
of an essential erythrocyte invasion complex (RH5/Ripr/CyRPA) and a target of potent cross …

Malaria vaccine development is hampered by extensive antigenic variation and complex life
stages of Plasmodium species. Vaccine development has focused on a small number of …